<DOC>
	<DOCNO>NCT01266174</DOCNO>
	<brief_summary>The purpose study determine eltoprazine ( adjunct anti-psychotic medication ) improve one aspect cognitive impairment adult schizophrenic patient .</brief_summary>
	<brief_title>Effects Eltoprazine Cognitive Impairment Associated With Schizophrenia ( CIAS ) Adults</brief_title>
	<detailed_description>Schizophrenia common highly disable psychiatric disorder population prevalence around 1 % . The manifestation schizophrenia fall three major domain : 1 ) `` positive '' symptom , delusion , hallucination , disorganization behavior ; 2 ) `` negative symptom , '' include social withdrawal , lack motivation , reduce expression affect ; 3 ) cognitive dysfunction . Cognitive deficit see patient schizophrenia . Eltoprazine agonist effect 5-HT1A 5-HT1B receptor , suggest drug may useful normalize prefrontal cognitive ability , reduce aggression impulsivity , improve cognitive function schizophrenia . This study compare effect Eltoprazine ( adjunctive treatment anti-psychotics ) Placebo Adults DSM IV/DSM IV TR diagnosis schizophrenia , potentially improve one dimension cognitive impairment associate schizophrenia .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Eltoprazine</mesh_term>
	<criteria>Males Females , 1865 year age , meet DSMIVTR schizophrenia . Must test negative pregnancy time enrollment base pregnancy test &amp; agrees use birth control study . Performance less max cutoff ( parenthesis ) ONE follow MCCB test : ) Letternumber span ( 20 ) ; ii ) HVLT total ( 31 ) ; iii ) CPT dprime ( 3.47 ) BPRS Hallucinatory Behavior Unusual Thought Content item score ≤ 5 BPRS Conceptual Disorganization item score ≤ 4 SimpsonAngus Scale total score ≤ 6 CDRS total score ≤ 10 Able complete baseline MCCB validly assess tester WTAR raw score ≥ 6 Be treat one follow second generation antipsychotic : risperidone , olanzapine , quetiapine , asenapine , iloperidone paliperidone previous two month , change dose last month , injectable depot antipsychotic ( fluphenazine , haloperidol decanoate , risperdal Consta paliperidone sustenna ) change last 3 month Laboratory result must show clinically significant abnormality . Must ECG QTc measurement perform Screening clinically significant . Must negative drug screen . Current treatment one follow antipsychotic : clozapine , aripiprazole , lurasidone ziprasidone . Current treatment anticholinergic drug dose 2 mg daily benztropine , 5 mg per day trihexyphenidyl , 50 mg day diphenhydramine . Current treatment benzodiazepine dose 10 mg diazepam ( equivalent another drug ) . Patients DSMIV diagnosis alcohol substance abuse within last month DSMIV diagnosis alcohol substance dependence within last 6 month . Have significant suicide attempt within one year Visit 1 , answer yes question 3 , 4 5 CSSRS Visit 1 , currently risk suicide opinion Investigator . Patients hx significant head injury/trauma . Patients clinically significant neurological , metabolic , hepatic , hematological , pulmonary , cardiovascular , gastrointestinal , and/or urological disorder . Insulindependent diabetic clinically stable whose baseline fast glucose 200 le may include . Clinically significant abnormality PE , ECG , lab assessment . Clinically significant renal disease ( e.g . chronic renal insufficiency GFR &lt; 60 , inflammatory disease require medication , acute renal failure ) . Pregnant woman woman childbearing potential , either surgicallysterile use appropriate method birth control . Women breastfeed Have TSH level consistent hyperthyroidism hypothyroidism . Patients previously diagnose hyperthyroidism hypothyroidism , treat stable dose thyroid supplement least past 3 month , clinically chemically euthyroid allow participate study . Have significant prior current medical condition , judgment investigator , could exacerbate compromised study drug . Have medical condition would increase sympathetic nervous system activity markedly.Patients take medication daily basis ( example , albuterol , inhalation aerosol , pseudoephedrine ) , sympathomimetic activity enrol . Used MAOIs 2 week ( 14 day ) prior Baseline . Have use SSRI , 5HT1A agonist serotoninmediated treatment reason 4 week prior Baseline . Have current hypertension despite treatment . Have receive treatment within last 60 day drug receive regulatory approval indication time study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>CIAS</keyword>
	<keyword>Cognition</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Eltoprazine</keyword>
</DOC>